Trial reportThe Journal of dermatology2018
Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study.
Trial report in The Journal of dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Epidemiological, Genetic, Clinical, and Treatment Differences of Generalized Pustular Psoriasis and Acrodermatitis Continua of Hallopeau Across Ethnicities: A Systematic Review.American journal of clinical dermatology · 2025Pooled it
- The efficacy and safety of spesolimab in patients with generalized pustular psoriasis flares: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis.Frontiers in immunology · 2024Pooled it
- Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.The Journal of dermatology · 2023Trial
- Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review.Dermatology and therapy · 2025Review
- Treatment Status for Generalized Pustular Psoriasis in Japanese Patients: A Retrospective Chart Review.Dermatology and therapy · 2025Article
- Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching-A Japanese e-Delphi Survey.Dermatology and therapy · 2025Article
- Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.Dermatology and therapy · 2024Review
- New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.Pharmaceutics · 2024Review
- Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.Frontiers in immunology · 2024Article
- Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date.Psoriasis (Auckland, N.Z.) · 2024Review
- Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?Clinical, cosmetic and investigational dermatology · 2023Review
- Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.Dermatology and therapy · 2022Article
- The Impact of Pruritus on the Quality of Life and Sleep Disturbances in Patients Suffering from Different Clinical Variants of Psoriasis.Journal of clinical medicine · 2022Article
- Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.Dermatology and therapy · 2022Article
- Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient.Dermatologic therapy · 2022Article
- The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis Registry.Journal of psoriasis and psoriatic arthritis · 2022Article
- Clinical Disease Measures in Generalized Pustular Psoriasis.American journal of clinical dermatology · 2022Review
- Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States.JAMA dermatology · 2022Article
- Acute Generalized Pustular Psoriasis Developed Resistance to Adalimumab Was Successfully Treated with Narrowband Ultraviolet B and Acitretin: A Case Report.Clinical, cosmetic and investigational dermatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
Abstract
A phase 3, multicenter, open-label, 52-week study investigated the efficacy and safety of adalimumab 80 mg at week 0 followed by adalimumab 40 mg every other week (option to escalate to 80 mg when necessary) in Japanese patients with generalized pustular psoriasis (GPP). Adults (aged 15-75 years) with GPP, total skin score (overall erythema area, erythema area with pustules, and edema area) of 3 or more, and erythema with pustules (skin score, ≥1) based on the 2014 Japanese Dermatological Association severity index of GPP were enrolled. The primary efficacy end-point was clinical response at week 16 (non-responder imputation), defined as achieving remission (total skin score, 0) or improvement from baseline (reduction of ≥1 point from a baseline total skin score of 3 or ≥2 points from a baseline total skin score of ≥4). Of 10 enrolled patients (mean disease duration, 10.6 years), seven patients, including three with the dose escalated to 80 mg every other week before week 15, achieved clinical response at week 16, and five achieved clinical response at week 52. Mean change from baseline total GPP score was -4.6 at week 16 (n = 8) and -6.0 at week 52 (n = 5); change in total skin score was -3.1 (n = 8) and -4.2 (n = 5), respectively. Nine patients experienced one or more adverse events and three experienced serious adverse events. The most common adverse events were nasopharyngitis, pruritus and hypoalbuminemia. In conclusion, adalimumab was effective and well tolerated for up to 52 weeks in the treatment of Japanese patients with GPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.